Agency recommends moving away from testing each individual donation to testing pooled donations
MONDAY, July 9, 2018 (HealthDay News) — Individual blood donations will no longer need to be tested for the Zika virus, according to the U.S. Food and Drug Administration.
“When Zika virus first emerged, the unknown course of the epidemic and the observed severe effects from the disease indicated that individual donor testing was needed to ensure the continued safety of the blood supply,” Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, explained in an agency press release. “Now, given the significant decrease in cases of Zika virus infection in the United States and its territories, we are moving away from testing each individual donation to testing pooled donations.”
Pooled testing of donations is considered less burdensome and more cost-effective for blood establishments. However, the FDA will continue to monitor the situation closely, and if necessary, reconsider what measures are needed to maintain the safety of the blood supply.
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators 
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients 
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors 
NEWS2 Scores Can ID Patients With Suspected Sepsis Needing Timely Treatment .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Therapeutic Hypothermia Duration Explored in Comatose OHCA Survivors 
CHEST Issues Guidelines for Management of Adult Bronchiectasis 
Autonomous Oxygen Titration Increases Proportion of Time in Normoxemia 
